1 ratings / 5 average

Incorporating the New IASLC Staging System for Lung Cancer within 
Daily Practice 

Ramón Rami-Porta, MD1, and Peter Goldstraw, MB, FRCS2

The publication of the seventh edition of the tumor, node, metastasis (TNM) classification of lung cancer was the culmination of a dozen years of activities carried out by the International Staging Committee of the International Association for the Study of Lung Cancer (IASLC) [1]. The primary objective of the IASLC Lung Cancer Staging Project was to update and validate the TNM classification of lung cancer based on a large international database [2]. The proposed changes to the sixth edition of the TNM classification, derived from the analyses of this database, were published in peer-reviewed journals for public scrutiny and discussion [3–10], internally and externally validated [11], accepted by the International Union Against Cancer and the American Joint Committee on Cancer, and published as identical texts in those organizations’ respective staging manuals [12,13]. In addition to the new staging classification, much background material has been published by the IASLC in the first site-specific guidance on lung cancer: the IASLC Staging Manual in Thoracic Oncology [1].

Return to top


Third-Line Treatment in Advanced NSCLC
Juneko E Grilley-Olson, Thomas E Stinchcombe, and Mark A Socinski
CML Lung Cancer
The Role of EGFR-TKIs in the 
Management of NSCLC

Herbert H Loong MBBS, MRCP1, Tony S Mok MD, FRCP(C)1,2
CML Lung Cancer
Treatment of Large-Cell Neuroendocrine Carcinoma of the Lung
Ioannis Gounaris, MRCP, and Hugo ER Ford, MD, FRCP
CML Lung Cancer
The Role of Systemic Therapy in Patients with NSCLC and Brain Metastases
Thomas Harris, MD1, and David Schiff, MD2
CML Lung Cancer
Surgery versus Radiotherapy 
in Early-Stage NSCLC
Branislav Jeremi´c1, Anusheel Munshi2, Francesc Casas3, Igor Stojkovski4, 
Zeljko Dobric1, Susovan Banerjee2, and JP Agarwal2

CML Lung Cancer
Cancer Stem Cells in Lung and Pleural Malignancies
Silvia Baiguera, PhD1, Madhuri Kalathur1, and Paolo Macchiarini, MD, PhD1,2

CML Lung Cancer